Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases

Executive Summary

The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.

Advertisement

Related Content

Takeda Poised To Move Into Pharma Top 10 With Shire Combination
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Europe's Biopharma Sector Could Be In For Bumper Year
Appointments: EMD Serono, Cellectis, Shire, Bayer, Biogen, Horizon, Alligator, Faron, Ironwood, Vectura
Shire Explores Robotic Pill Potential For Hemophilia
Interview: Joerg Moeller, Bayer Development Chief, On R&D Consolidation
Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel